197 related articles for article (PubMed ID: 21520937)
1. Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies.
Wang X; Wu S; Xu D; Xie D; Guo H
J Chem Inf Model; 2011 May; 51(5):1074-82. PubMed ID: 21520937
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and molecular docking studies of Angiotensin converting enzyme with inhibitor lisinopril and amyloid Beta Peptide.
Jalkute CB; Barage SH; Dhanavade MJ; Sonawane KD
Protein J; 2013 Jun; 32(5):356-64. PubMed ID: 23660814
[TBL] [Abstract][Full Text] [Related]
3. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme.
Natesh R; Schwager SL; Evans HR; Sturrock ED; Acharya KR
Biochemistry; 2004 Jul; 43(27):8718-24. PubMed ID: 15236580
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.
Natesh R; Schwager SL; Sturrock ED; Acharya KR
Nature; 2003 Jan; 421(6922):551-4. PubMed ID: 12540854
[TBL] [Abstract][Full Text] [Related]
5. Validated ligand mapping of ACE active site.
Kuster DJ; Marshall GR
J Comput Aided Mol Des; 2005 Aug; 19(8):609-15. PubMed ID: 16307311
[TBL] [Abstract][Full Text] [Related]
6. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
[TBL] [Abstract][Full Text] [Related]
7. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril.
Watermeyer JM; Kröger WL; O'Neill HG; Sewell BT; Sturrock ED
Biochem J; 2010 Apr; 428(1):67-74. PubMed ID: 20233165
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme open for business: structural insights into the subdomain dynamics.
Cozier GE; Lubbe L; Sturrock ED; Acharya KR
FEBS J; 2021 Apr; 288(7):2238-2256. PubMed ID: 33067882
[TBL] [Abstract][Full Text] [Related]
9. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.
Masuyer G; Akif M; Czarny B; Beau F; Schwager SL; Sturrock ED; Isaac RE; Dive V; Acharya KR
FEBS J; 2014 Feb; 281(3):943-56. PubMed ID: 24289879
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb).
Sturrock ED; Lubbe L; Cozier GE; Schwager SLU; Arowolo AT; Arendse LB; Belcher E; Acharya KR
Biochem J; 2019 May; 476(10):1553-1570. PubMed ID: 31072910
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme.
Zhou M; Du K; Ji P; Feng W
Biophys Chem; 2012 Jul; 168-169():60-6. PubMed ID: 22835627
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
Nchinda AT; Chibale K; Redelinghuys P; Sturrock ED
Bioorg Med Chem Lett; 2006 Sep; 16(17):4616-9. PubMed ID: 16784843
[TBL] [Abstract][Full Text] [Related]
14. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
15. Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools.
Alfaro S; Navarro-Retamal C; Caballero J
Mini Rev Med Chem; 2020; 20(14):1436-1446. PubMed ID: 31889494
[TBL] [Abstract][Full Text] [Related]
16. Surface plasmon resonance analysis of the binding mechanism of pharmacological and peptidic inhibitors to human somatic angiotensin I-converting enzyme.
Zidane F; Zeder-Lutz G; Altschuh D; Girardet JM; Miclo L; Corbier C; Cakir-Kiefer C
Biochemistry; 2013 Dec; 52(48):8722-31. PubMed ID: 24168709
[TBL] [Abstract][Full Text] [Related]
17. Structure of angiotensin I-converting enzyme.
Sturrock ED; Natesh R; van Rooyen JM; Acharya KR
Cell Mol Life Sci; 2004 Nov; 61(21):2677-86. PubMed ID: 15549168
[TBL] [Abstract][Full Text] [Related]
18. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme.
Perich RB; Jackson B; Johnston CI
Eur J Pharmacol; 1994 Feb; 266(3):201-11. PubMed ID: 8174603
[TBL] [Abstract][Full Text] [Related]
19. Structural features of angiotensin-I converting enzyme catalytic sites: conformational studies in solution, homology models and comparison with other zinc metallopeptidases.
Spyroulias GA; Galanis AS; Pairas G; Manessi-Zoupa E; Cordopatis P
Curr Top Med Chem; 2004; 4(4):403-29. PubMed ID: 14965309
[TBL] [Abstract][Full Text] [Related]
20. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.
Polakovičová M; Jampílek J
Med Chem; 2019; 15(6):574-587. PubMed ID: 31084594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
